To see the issue content and the abstract you do not have to login
Please login to download the full articles

Emailadres
Password
Lost password?      Click here!

If you do not have a subscription to Rhinology please consider to take one.
Click here to become a member of the European Rhinologic Society and a subscriber to the journal `RHINOLOGY`, beginning 2019. Subscription including membership fee: Euro 139.-

If you only want to buy this paper please click here
The price of the paper is 25 euro.


Risk of mortality and cardiovascular events following macrolide prescription in chronic rhinosinusitis patients: a cohort study using linked primary care electronic health records

Volume: - Issue:

Firstpage: 0 - Lastpage: 0

E. Williamson - S. Denaxas - S. Morris - C.S. Clarke - M. Thomas - H. Evans - K. Direk - A. Gonzalez-Izquierdo - P. Little - V. Lund - H. Blackshaw - A. Schilder - C. Philpott - C. Hopkins - J. Carpenter - On behalf of the MACRO programme team

BACKGROUND: Macrolide antibiotics have demonstrated important anti-inflammatory and immunomodulatory properties in chronic rhinosinusitis (CRS) patients. However, reports of increased risks of cardiovascular events have led to safety concerns. We investigated the risk of all-cause and cardiac death, and cardiovascular outcomes, associated with macrolide use.
METHODOLOGY: Observational cohort (1997-2016) using linked data from the Clinical Practice Research Datalink, Hospital Episodes Statistics, and the Office for National Statistics. Patients aged 16-80 years with CRS prescribed a macrolide antibiotic or penicillin were included, comparing prescriptions for macrolide antibiotics to penicillin. Outcomes were all-cause mortality, cardiac death, myocardial infarction, stroke, diagnosis of peripheral vascular disease, and cardiac arrhythmia.
RESULTS: Analysis included 320,798 prescriptions received by 66,331 patients. There were 3,251 deaths, 815 due to cardiovascular causes, 925 incident myocardial infarctions, 859 strokes, 637 diagnoses of peripheral vascular disease, and 1,436 cardiac arrhythmias. A non-statistically significant trend towards increased risk of myocardial infarction during the first 30 days following macrolide prescription was observed. No statistically significant short- or long-term risks were observed for macrolide prescription. No significant risks were identified for clarithromycin in particular.
CONCLUSIONS: Although not statistically significant, our best estimates suggest an increased short-term risk of myocardial infarction in patients with CRS following macrolide prescription, supporting previous observational evidence. However, confounding by indication remains a possible explanation for this apparent increased risk. We found no evidence of longer term increased risks.

E. Williamson - S. Denaxas - S. Morris - C.S. Clarke - M. Thomas - H. Evans - K. Direk - A. Gonzalez-Izquierdo - P. Little - V. Lund - H. Blackshaw - A. Schilder - C. Philpott - C. Hopkins - J. Carpenter - On behalf of the MACRO programme team - Risk of mortality and cardiovascular events following macrolide prescription in chronic rhinosinusitis patients: a cohort study using linked primary care electronic health records
Rhinology -: 0-0, 0000